Tags

Type your tag names separated by a space and hit enter

Early conversion from oral morphine to transdermal fentanyl in patients with cancer pain.
Hepatogastroenterology. 2008 Sep-Oct; 55(86-87):1545-8.H

Abstract

BACKGROUND/AIMS

The aim of this study is to prove that an early conversion from oral morphine to transdermal fentanyl is an effective and safe treatment modality for patients with cancer pain.

METHODOLOGY

Early conversion to transdermal fentanyl was evaluated for patients with cancer pain (VAS > or = 4) by administering 20-30 mg of morphine.

RESULTS

The early conversion to transdermal fentanyl improved cancer pain in comparison to oral morphine. The mean VAS score improved to 2.6 +/- 2.8 after treatment, whereas the mean VAS score was 5.67 +/- 2.4 before treatment by transdermal fentanyl. Eighteen of 24 patients (75%) were responders due to an early conversion by the VAS score, and the mean VAS score after transdermal fentanyl was 1.2 +/- 0.9 in responders. Finally, 66.7% of all patients received from 2.5 mg to 5.0 mg of transdermal fentanyl. The VAS score before conversion from oral morphine to transdermal fentanyl showed a significant difference (responder vs. non-responder: 4.7 +/- 1.8 vs. 8.5 +/- 1.4, P<0.001). Rescue treatment for cancer pain was required for 16 series in 13 patients. Vomiting, nausea, constipation, and drowsiness were observed as adverse effects. However, the nausea symptoms significantly improved after treatment with transdermal fentanyl (P<0.05).

CONCLUSIONS

Early conversion from oral morphine to transdermal fentanyl helped to effectively relieve cancer pain while improving the effects of morphine induced nausea.

Authors+Show Affiliations

Second Department of Surgery, Wakayama Medical University, School of Medicine, 811-1 Kimiidera, Wakayama 641-8510, Japan.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article

Language

eng

PubMed ID

19102339

Citation

Tani, Masaji, et al. "Early Conversion From Oral Morphine to Transdermal Fentanyl in Patients With Cancer Pain." Hepato-gastroenterology, vol. 55, no. 86-87, 2008, pp. 1545-8.
Tani M, Fuku A, Terashita S, et al. Early conversion from oral morphine to transdermal fentanyl in patients with cancer pain. Hepatogastroenterology. 2008;55(86-87):1545-8.
Tani, M., Fuku, A., Terashita, S., Kashiwagi, H., Yukawa, H., & Yamaue, H. (2008). Early conversion from oral morphine to transdermal fentanyl in patients with cancer pain. Hepato-gastroenterology, 55(86-87), 1545-8.
Tani M, et al. Early Conversion From Oral Morphine to Transdermal Fentanyl in Patients With Cancer Pain. Hepatogastroenterology. 2008 Sep-Oct;55(86-87):1545-8. PubMed PMID: 19102339.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Early conversion from oral morphine to transdermal fentanyl in patients with cancer pain. AU - Tani,Masaji, AU - Fuku,Akito, AU - Terashita,Shiro, AU - Kashiwagi,Hideo, AU - Yukawa,Hiroshi, AU - Yamaue,Hiroki, PY - 2008/12/24/entrez PY - 2008/12/24/pubmed PY - 2009/1/28/medline SP - 1545 EP - 8 JF - Hepato-gastroenterology JO - Hepatogastroenterology VL - 55 IS - 86-87 N2 - BACKGROUND/AIMS: The aim of this study is to prove that an early conversion from oral morphine to transdermal fentanyl is an effective and safe treatment modality for patients with cancer pain. METHODOLOGY: Early conversion to transdermal fentanyl was evaluated for patients with cancer pain (VAS > or = 4) by administering 20-30 mg of morphine. RESULTS: The early conversion to transdermal fentanyl improved cancer pain in comparison to oral morphine. The mean VAS score improved to 2.6 +/- 2.8 after treatment, whereas the mean VAS score was 5.67 +/- 2.4 before treatment by transdermal fentanyl. Eighteen of 24 patients (75%) were responders due to an early conversion by the VAS score, and the mean VAS score after transdermal fentanyl was 1.2 +/- 0.9 in responders. Finally, 66.7% of all patients received from 2.5 mg to 5.0 mg of transdermal fentanyl. The VAS score before conversion from oral morphine to transdermal fentanyl showed a significant difference (responder vs. non-responder: 4.7 +/- 1.8 vs. 8.5 +/- 1.4, P<0.001). Rescue treatment for cancer pain was required for 16 series in 13 patients. Vomiting, nausea, constipation, and drowsiness were observed as adverse effects. However, the nausea symptoms significantly improved after treatment with transdermal fentanyl (P<0.05). CONCLUSIONS: Early conversion from oral morphine to transdermal fentanyl helped to effectively relieve cancer pain while improving the effects of morphine induced nausea. SN - 0172-6390 UR - https://www.unboundmedicine.com/medline/citation/19102339/Early_conversion_from_oral_morphine_to_transdermal_fentanyl_in_patients_with_cancer_pain_ L2 - http://www.diseaseinfosearch.org/result/5395 DB - PRIME DP - Unbound Medicine ER -